Cargando…

S294: MARIBAVIR (MBV) VERSUS INVESTIGATOR-ASSIGNED THERAPY FOR REFRACTORY CYTOMEGALOVIRUS (CMV) INFECTION: SUBGROUPS ANALYSES OF PHASE 3 STUDY BY RESISTANCE STATUS KNOWLEDGE REPORTED BY INVESTIGATORS.

Detalles Bibliográficos
Autores principales:	Duarte, Rafael F, Alain, Sophie, Chemaly, Roy F, Montoto, Carmen, de Castro-Orós, Isabel, Maertens, Johan, Tagarro, Ignacio
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Lippincott Williams & Wilkins 2023
Materias:	Oral Sessions
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10428459/ http://dx.doi.org/10.1097/01.HS9.0000968088.69924.4d

Ejemplares similares

Maribavir for Refractory Cytomegalovirus Infections With or Without Resistance Post-Transplant: Results From a Phase 3 Randomized Clinical Trial( )
por: Avery, Robin K, et al.
Publicado: (2021)

Evaluating the Safety of Maribavir for the Treatment of Cytomegalovirus
por: Gandhi, Ronak G, et al.
Publicado: (2022)

21. Efficacy and Safety of Maribavir as a Rescue Treatment for Investigator Assigned Therapy in Transplant Recipients With Refractory or Resistant Cytomegalovirus Infections in the SOLSTICE Study: Phase 3 Trial Results
por: Pereira, Marcus, et al.
Publicado: (2021)

Maribavir for Cytomegalovirus Treatment in the Real World—Not a Silver Bullet
por: Fung, Monica, et al.
Publicado: (2022)

Population pharmacokinetic modeling and simulation of maribavir to support dose selection and regulatory approval in adolescents with posttransplant refractory cytomegalovirus
por: Sun, Kefeng, et al.
Publicado: (2023)

A Mortality Analysis of Letermovir Prophylaxis for Cytomegalovirus (CMV) in CMV-seropositive Recipients of Allogeneic Hematopoietic Cell Transplantation
por: Ljungman, Per, et al.
Publicado: (2020)

The effects of maribavir on the autophosphorylation of ganciclovir resistant mutants of the cytomegalovirus UL97 protein
por: Shannon-Lowe, Claire D, et al.
Publicado: (2010)

Fast selection of maribavir resistant cytomegalovirus in a bone marrow transplant recipient
por: Schubert, Axel, et al.
Publicado: (2013)

A Mortality Analysis of the Cytomegalovirus (CMV) Infection Letermovir Prophylaxis Trial in CMV-Seropositive Recipients of Allogeneic Hematopoietic Cell Transplantation (HCT)
por: Maertens, Johan, et al.
Publicado: (2017)

Correction to: Maribavir for Refractory Cytomegalovirus Infections With or Without Resistance Post-Transplant: Results From a Phase 3 Randomized Clinical Trial
Publicado: (2023)

Drug Resistance Mutations and Associated Phenotypes Detected in Clinical Trials of Maribavir for Treatment of Cytomegalovirus Infection
por: Chou, Sunwen, et al.
Publicado: (2020)

1538. High Mortality of Cytomegalovirus (CMV) Pneumonia in Hematopietic Cell Transplant Recipients
por: Batista, Marjorie, et al.
Publicado: (2018)

Maribavir for Refractory or Resistant Cytomegalovirus Infections in Hematopoietic-cell or Solid-organ Transplant Recipients: A Randomized, Dose-ranging, Double-blind, Phase 2 Study
por: Papanicolaou, Genovefa A, et al.
Publicado: (2019)

Detection of Low Frequency Multi-Drug Resistance and Novel Putative Maribavir Resistance in Immunocompromised Pediatric Patients with Cytomegalovirus
por: Houldcroft, Charlotte J., et al.
Publicado: (2016)

Investigation of reactions at a momentum of 2.94 GeV/c
por: Barmin, V V, et al.
Publicado: (1971)

Cytomegalovirus (CMV)-specific cytotoxic T lymphocyte therapy resolve CMV diseases and refractory CMV infections in paediatric recipients of allogeneic haematopoietic stem cell transplantation
por: Wang, Xiaodong, et al.
Publicado: (2021)

Cytomegalovirus (CMV) Infection and Latency
por: O’Connor, Christine M.
Publicado: (2021)

Vuelo 294
por: Mendiola, Víctor Manuel, 1954-
Publicado: (1997)

Recombinant luciferase-expressing human cytomegalovirus (CMV) for evaluation of CMV inhibitors
por: He, Ran, et al.
Publicado: (2011)

S291: LONG-TERM SAFETY AND EFFICACY OF CMV/EBV-SPECIFIC T CELLS FOR CMV AND EBV CO-REACTIVATION AFTER HAPLOIDENTICAL STEM CELL TRANSPLANTATION
por: Xuying, Pei, et al.
Publicado: (2023)

Synthesis of New Imidazopyridine Nucleoside Derivatives Designed as Maribavir Analogues
por: Papadakis, Georgios, et al.
Publicado: (2020)

Conserved retinoblastoma protein-binding motif in human cytomegalovirus UL97 kinase minimally impacts viral replication but affects susceptibility to maribavir
por: Gill, Rachel B, et al.
Publicado: (2009)

Placental transfer of Letermovir & Maribavir in the ex vivo human cotyledon perfusion model. New perspectives for in utero treatment of congenital cytomegalovirus infection
por: Faure Bardon, Valentine, et al.
Publicado: (2020)

The genome and occlusion bodies of marine Penaeus monodon nudivirus (PmNV, also known as MBV and PemoNPV) suggest that it should be assigned to a new nudivirus genus that is distinct from the terrestrial nudiviruses
por: Yang, Yi-Ting, et al.
Publicado: (2014)

Successful Use of Heterologous CMV-Reactive T Lymphocyte to Treat Severe Refractory Cytomegalovirus (CMV) Infection in a Liver Transplanted Patient: Correlation of the Host Antiviral Immune Reconstitution with CMV Viral Load and CMV miRNome
por: Miele, Monica, et al.
Publicado: (2021)

Targeting cytomegalovirus (CMV) antigens for GBM immunotherapy
por: Nair, Smita K, et al.
Publicado: (2013)

Cytomegalovirus (CMV) seroprevalence in the adult population of Germany
por: Lachmann, Raskit, et al.
Publicado: (2018)

Acute Cytomegalovirus (CMV) Hepatitis in an Immunocompetent Adult
por: Zahid, Maleeha, et al.
Publicado: (2020)

Correlation of Cytomegalovirus (CMV) Disease Severity and Mortality With CMV Viral Burden in CMV-Seropositive Donor and CMV-Seronegative Solid Organ Transplant Recipients
por: McBride, Jacqueline M, et al.
Publicado: (2019)

S220: REAL-WORLD OUTCOMES OF BREXUCABTAGENE AUTOLEUCEL (BREXU-CEL) FOR RELAPSED OR REFRACTORY MANTLE CELL LYMPHOMA: A CIBMTR SUBGROUP ANALYSIS BY PRIOR TREATMENT
por: Ahmed, Nausheen, et al.
Publicado: (2023)

604 Risk Factors for Cytomegalovirus (CMV) Reactivation in CMV-seropositive Liver Transplant Patients
por: Bruminhent, Jackrapong, et al.
Publicado: (2014)

THE PREVALENCE OF CYTOMEGALOVIRUS (CMV) VIRURIA AMONG HOSPITALIZED CHILDREN AND THE RISK OF CMV ACQUISITION BY NURSES
por: Adler, Stuart P, et al.
Publicado: (1984)

Exploration of the yadokari/yadonushi nature of YkV3 and RnMBV3 in the original host and a model filamentous fungus
por: Sato, Yukiyo, et al.
Publicado: (2023)

1730. Outcomes of Patients With Detectable Cytomegalovirus (CMV) DNA at Randomization in the Double-blind, Placebo-Controlled Phase 3 Trial of Letermovir (LET) Prophylaxis for CMV-Seropositive Allogeneic Hematopoietic-Cell Transplantation (HCT) Recipients
por: Marty, Francisco M, et al.
Publicado: (2018)

Detection of cytomegalovirus (CMV) by digital PCR in stool samples for the non-invasive diagnosis of CMV gastroenteritis
por: Gu, Jia, et al.
Publicado: (2022)

1561. Outcomes of Resistant or Refractory CMV Infection in Recipients of Allogeneic Hematopoietic Cell Transplant
por: Artau, Annette, et al.
Publicado: (2018)

580. Refractory and Resistant CMV Infections in Hematopoietic Cell Transplant Recipients in the Letermovir Primary Prophylaxis Era
por: Sassine, Joseph, et al.
Publicado: (2020)

Effects of Maribavir on P‐Glycoprotein and CYP2D6 in Healthy Volunteers
por: Song, Ivy H., et al.
Publicado: (2019)

Cytomegalovirus Hyper Immunoglobulin for CMV Prophylaxis in Thoracic Transplantation
por: Rea, Federico, et al.
Publicado: (2016)

Detection of Cytomegalovirus (CMV) in Saliva of Congenitally Infected Neonates
por: Wissel, Mark, et al.
Publicado: (2017)

Cannot write session to /tmp/vufind_sessions/sess_ond75sb5ntitde5qd6tkn3e9i2